Graminex® Rye Pollen Achieves Novel Food Registration in China and Appoints Guangzhou Narnia Biotechnology as Their Authorized Distribution Partner
8.8.2023 03:00:00 EEST | Business Wire | Press release
Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China.
Graminex®, based in the United States, is the exclusive grower and manufacturer of rye pollen and a leader in the international dietary supplement industry, with products sold in more than 47 countries. Graminex’s vertically integrated manufacturing ensures quality, consistency, and efficacy of their products. Guangzhou Narnia Biotech will represent Graminex® Rye Pollen active ingredients, as well as the dietary supplements, primarily focusing on the areas of prostate health, women’s health, and liver support.
“We are very excited about the opportunity to market high quality dietary ingredients that have been recently registered in China,” said Daniel Guo, General Manager, Narnia Biotech. “Our market is increasingly looking for high-quality dietary products. Our cooperation with Graminex® will strengthen Narnia’s offering to our customers and is in line with Narnia’s strategy of partnering with innovative producers of unique ingredients.”
Heather J. May, CEO of Graminex® said, “Narnia Biotech has a reputation of unmatched customer service and technical capabilities, including lab testing and product formulation. I am confident that through their expertise and attention to product safety and quality assurance, they are the right distribution partner for Graminex in China.”
About Guangzhou Narnia Biotechnology Co., Ltd
Narina is headquartered in TIMES E-PARK, Tianhe District, Guangzhou, with an R&D Center in Guangzhou. Its branch in Beijing extends their network throughout China. Narnia’s mission to create a safe, natural, and nutritious life is based on commitments to integration and promotion of functional food ingredients. With current market trends and continuously developing formulation technology, Narnia provides customers one-stop procurement solutions, as well as value-added services such as market analysis, project launching, formula design, and production guidance. Visit www.narniabiotech.com.
About Graminex ® L.L.C.
Graminex® is the leading producer of solvent-free Graminex® Rye Pollen. Graminex® owns and manages over 6,500 farm acres in Ohio to meet customer’s needs. Graminex’s active ingredients are grown and processed for the dietary supplement, nutraceutical, pharmaceutical, food and skincare industries, focusing on prostate health, urinary care, menopausal support. Visit www.graminex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807107912/en/
Contact information
Colleen E. May
CBO
+1 (419) 278-1023
graminex@graminex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 14:12:00 EEST | Press release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom